Secretive? Moderna details its pipeline strategy at JPM but at least one critic bites back
Moderna outlined its pipeline strategy at JP Morgan this week, focusing specifically on five clinical-stage programs for new vaccines as a relatively low-risk approach to demonstrating that their messenger RNA technology and the platform work. But the kickback didn’t take long to strike, as a persistent critic at Stat picked at one troubled program while raising questions about the overall value of an entry-level approach focused on a high volume, low-margin business like vaccines.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.